FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981440981> ?p ?o ?g. }

• W2981440981 endingPage "4450" @default.
• W2981440981 startingPage "4436" @default.
• W2981440981 abstract "Brivanib, a promising tyrosine kinase inhibitor, is currently undergoing advanced stages of clinical evaluation for solid tumor therapy. In this work, we investigated possible interactions of this novel drug candidate with ABC drug efflux transporters and cytochrome P450 (CYP450) drug-metabolizing enzymes that participate in cancer multidrug resistance (MDR) and pharmacokinetic drug-drug interactions (DDIs). First, in accumulation experiments with various model substrates, we identified brivanib as an inhibitor of the ABCB1, ABCG2, and ABCC1 transporters. However, in subsequent combination studies employing 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide proliferation assays in both Madin-Darby canine kidney II (MDCKII) and A431 cellular models, only ABCG2 inhibition was revealed to be able to synergistically potentiate mitoxantrone effects. Advantageous to its possible use as MDR antagonist, brivanib's chemosensitizing properties were not impaired by activity of any of the MDR-associated ABC transporters, as observed in comparative viability assay in the MDCKII cell sublines. In incubation experiments with eight recombinant CYP450s, we found that brivanib potently inhibited CYP2C subfamily members and the CYP2B6 isoform. Finally, in induction studies, we demonstrated that brivanib upregulated ABCB1 and CYP1A2 messenger RNA levels in systemic cell models, although this interaction was not significantly manifested at a functional level. In conclusion, brivanib exhibits potential to cause clinically relevant pharmacokinetic DDIs and act as a modulator of ABCG2-mediated MDR. Our findings might be used as an important background for subsequent in vivo investigations and pave the way for the safe and effective use of brivanib in oncological patients." @default.
• W2981440981 created "2019-11-01" @default.
• W2981440981 creator A5008166908 @default.
• W2981440981 creator A5009579592 @default.
• W2981440981 creator A5012745137 @default.
• W2981440981 creator A5013089143 @default.
• W2981440981 creator A5016369220 @default.
• W2981440981 creator A5031445293 @default.
• W2981440981 creator A5054635403 @default.
• W2981440981 creator A5079261300 @default.
• W2981440981 creator A5082008030 @default.
• W2981440981 creator A5085056121 @default.
• W2981440981 date "2019-10-21" @default.
• W2981440981 modified "2023-10-16" @default.
• W2981440981 title "Brivanib Exhibits Potential for Pharmacokinetic Drug–Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes" @default.
• W2981440981 cites W1184100163 @default.
• W2981440981 cites W1773543011 @default.
• W2981440981 cites W1949827505 @default.
• W2981440981 cites W1981140460 @default.
• W2981440981 cites W1982424532 @default.
• W2981440981 cites W1987821958 @default.
• W2981440981 cites W2005998697 @default.
• W2981440981 cites W2007690844 @default.
• W2981440981 cites W2010427019 @default.
• W2981440981 cites W2033520329 @default.
• W2981440981 cites W2045750704 @default.
• W2981440981 cites W2046000826 @default.
• W2981440981 cites W2051684210 @default.
• W2981440981 cites W2055437752 @default.
• W2981440981 cites W2056772956 @default.
• W2981440981 cites W2072156953 @default.
• W2981440981 cites W2081138086 @default.
• W2981440981 cites W2103562758 @default.
• W2981440981 cites W2104477408 @default.
• W2981440981 cites W2106720606 @default.
• W2981440981 cites W2111080882 @default.
• W2981440981 cites W2123022805 @default.
• W2981440981 cites W2126848629 @default.
• W2981440981 cites W2130244550 @default.
• W2981440981 cites W2130482724 @default.
• W2981440981 cites W2147328441 @default.
• W2981440981 cites W2152889463 @default.
• W2981440981 cites W2163012126 @default.
• W2981440981 cites W2171791920 @default.
• W2981440981 cites W2278073240 @default.
• W2981440981 cites W2597575764 @default.
• W2981440981 cites W2599363274 @default.
• W2981440981 cites W2600452401 @default.
• W2981440981 cites W2732949430 @default.
• W2981440981 cites W2744882241 @default.
• W2981440981 cites W2766922062 @default.
• W2981440981 cites W2796552195 @default.
• W2981440981 cites W2799449726 @default.
• W2981440981 cites W2944724114 @default.
• W2981440981 doi "https://doi.org/10.1021/acs.molpharmaceut.9b00361" @default.
• W2981440981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31633365" @default.
• W2981440981 hasPublicationYear "2019" @default.
• W2981440981 type Work @default.
• W2981440981 sameAs 2981440981 @default.
• W2981440981 citedByCount "20" @default.
• W2981440981 countsByYear W29814409812020 @default.
• W2981440981 countsByYear W29814409812021 @default.
• W2981440981 countsByYear W29814409812022 @default.
• W2981440981 countsByYear W29814409812023 @default.
• W2981440981 crossrefType "journal-article" @default.
• W2981440981 hasAuthorship W2981440981A5008166908 @default.
• W2981440981 hasAuthorship W2981440981A5009579592 @default.
• W2981440981 hasAuthorship W2981440981A5012745137 @default.
• W2981440981 hasAuthorship W2981440981A5013089143 @default.
• W2981440981 hasAuthorship W2981440981A5016369220 @default.
• W2981440981 hasAuthorship W2981440981A5031445293 @default.
• W2981440981 hasAuthorship W2981440981A5054635403 @default.
• W2981440981 hasAuthorship W2981440981A5079261300 @default.
• W2981440981 hasAuthorship W2981440981A5082008030 @default.
• W2981440981 hasAuthorship W2981440981A5085056121 @default.
• W2981440981 hasConcept C104317684 @default.
• W2981440981 hasConcept C109650736 @default.
• W2981440981 hasConcept C112705442 @default.
• W2981440981 hasConcept C114851261 @default.
• W2981440981 hasConcept C121608353 @default.
• W2981440981 hasConcept C126322002 @default.
• W2981440981 hasConcept C133936738 @default.
• W2981440981 hasConcept C149011108 @default.
• W2981440981 hasConcept C181199279 @default.
• W2981440981 hasConcept C185592680 @default.
• W2981440981 hasConcept C200082930 @default.
• W2981440981 hasConcept C2778820342 @default.
• W2981440981 hasConcept C2780035454 @default.
• W2981440981 hasConcept C44312359 @default.
• W2981440981 hasConcept C50605568 @default.
• W2981440981 hasConcept C512196 @default.
• W2981440981 hasConcept C526171541 @default.
• W2981440981 hasConcept C55493867 @default.
• W2981440981 hasConcept C71924100 @default.
• W2981440981 hasConcept C86803240 @default.
• W2981440981 hasConcept C89423630 @default.
• W2981440981 hasConcept C98274493 @default.
• W2981440981 hasConceptScore W2981440981C104317684 @default.

• next